# Asherbio

**Canonical:** https://apis.io/providers/asherbio/  
**Website:** https://asherbio.com  
**APIs profiled:** 0

Asherbio is a biopharmaceutical company focused on developing cis‑targeted immunotherapies that selectively activate immune cells to treat cancer and other diseases. Their platform aims to improve efficacy and reduce side effects by precisely targeting the immune response. Asher Bio’s pipeline includes candidates such as Etakafusp alfa, AB821, and AB359, with ongoing clinical collaborations and presentations at major oncology meetings. The company emphasizes innovative approaches to immune cell targeting, aiming to restore hope, health, and happiness for patients.

## Kin Score — 9.0 / 100 (minimal)

Scored 2026-10-23 under rubric 0.25.0. Trend: flat (+0.0 from 9.0).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Access Clarity | 21.1 |

Regulatory layer — **Horizontal (data, software, accessibility, platform)**: 13.7 (matched via fallback).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |
| Pagination Ratio | na |
| Operation Distinctiveness | na |

## Security (1)

- **Asherbio Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Biopharma, Immunotherapy, Oncology, Cis-targeted, Biotechnology

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/asherbio/). Scores are computed from the provider's own public artifacts under a published rubric.